En direct

Le Centre de Recherche en Cancérologie de Marseille fête ses 50 ans ! -

Feb 2022 Journal of the National Cancer Institute

RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.


Through analysis of preclinical models from endocrine receptor (ER)−/HER2+ and triple-negative (TN) inflammatory breast cancers (BCs) and of clinical BC samples, Villodre et al. (1) suggest that NDRG1 critically contributes to tumor growth and metastasis in aggressive ER-negative BCs. NDRG1 depletion reduces colony formation, migration, and invasion; number of tumor-initiating cells; and mTOR/AKT signaling in vitro and primary tumor growth and brain metastasis in vivo. NDRG1 expression is associated with aggressiveness features of clinical samples (ER−, TNBC, HER2+, high grade, metastatic samples) and shorter overall survival in multivariate analysis, including pathological stage and ER status. Because previous literature describes NDRG1 as a metastasis suppressor in less aggressive ER+ BC cell lines, the authors suggest that “NDRG1 has a context-dependent function in BC.” In fact, the clinical relevance of NDRG1 expression in BC has never been assessed in series large enough to allow analysis by molecular subtype. To fill this gap, we retrospectively examined NDRG1 mRNA expression in 8982 primary BC samples pooled from 36 public datasets, including notably 5929 ER+/HER2− and 1936 TN cases.